Helping our patient communities and advancing knowledge in our therapy areas is part of our corporate responsibility.
It is our mission to discover, develop, and deliver innovative therapies that improve patients' quality of life.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
See the research that is done to find out if medical treatments can improve people's health.
Every day at CSL Behring, we work as if someone's life depends on it, because it does.
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions
Help us deliver on our promise to save lives and protect the health of people.
Make you well-being a priority. It's important and so are you.
Vita means life. In this section, we share stories aimed at providing insight about, and awareness of, the ever-evolving promise of biotechnology.
Visit CSL Behring's newsroom to find recent news releases, archived releases, and media contacts.
News from CSL Behring
UQ, CEPI and CSL partner for COVID-19
• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate • …
Development of COVID-19 immunoglobulin commences
Plasma-derived therapeutic with potential to treat serious complications of COVID-19.
COVID-19 Update
CSL continues to provide medicines to patients around the world.
CSL Donates to Indonesian Relief Operations
CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunam…
CSL a Top 100 Company for Diversity & Inclusion
Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index
First SCIg Approved for CIDP
HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP
World Haemophilia Day
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia
Patient Enrolled in CSL112 Clinical Trial
The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medical centers around the world.
Making Forbes’ Top Global Employers List
Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth
Popular search terms:
Americas
Asia Pacific
Europe
